BioSpace News Archive

The Parkinson’s Foundation announced the University of Miami Miller School of Medicine is a new site for PD GENEration: Mapping the Future of Parkinson’s Disease, a first-of-its-kind national initiative that offers genetic testing and counseling for people with Parkinson’s disease (PD) at no cost.

NeuroSense Therapeutics, a biotechnology company developing treatments for neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS), based on a novel combination drug therapy aiming at slowing or halting the disease progression, announces the successful completion of its first Phase IIa study.

Wugen Inc., a biotechnology company developing novel, universal allogeneic cell therapy platforms, today announced that it has entered into an exclusive license agreement with US-based HCW Biologics Inc. (HCW) for the use of their proprietary fusion molecules to manufacture Wugen’s cellular therapeutics for the treatment of cancer.

Ichnos Sciences Inc., a global biotechnology company developing innovative biologic treatments in oncology and autoimmune diseases, today named Michael D. Price as Chief Financial Officer (CFO), effective immediately.

Sengenics, the Functional Proteomics Company, today announced the commercial launch of the Sengenics AxCESS research services suite which features three new KREX-based functional protein arrays developed for higher throughput and cost-effective immuno-proteomics applications.

ObvioHealth, a global virtual research organization or VRO, today announced the launch of a hybrid clinical trial for the treatment of COVID-19, using an innovative study design with digital data capture to remotely monitor patient vitals.

Neurolief, an innovator in neurotechnology, announces the company has received Food and Drug Administration (FDA) clearance for its Relivion® system.

PCI Pharma Services, a leading pharmaceutical and biopharmaceutical global outsourcing solutions provider, announced that Tom De Weerdt has joined the Company as Senior Vice President, Chief Financial Officer.

Molecular Targeting Technologies, Inc. (MTTI), a clinical stage radiopharmaceutical therapy company focused on therapies for rare diseases, announced today the approval of an Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA). It enables a Phase I clinical study of the Safety and Dosimetry of its lead product, EBTATE (177Lu-DOTA-EB-TATE)

Milestone Scientific Inc. (NYSE American:MLSS), a leading developer of computerized drug delivery instruments that provides virtually painless and precise injections, today announced it has begun selling CompuFlo® / CathCheck™ disposables to the Medical University of South Carolina (MUSC).